secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2026-07-07T20:04:11+00:00
Accession:  0001193125-26-297454
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor BioPharma appoints David Zaccardelli to board; director Andrew Levin resigns
--------------------------------------------------------------------------------

- Andrew Levin resigned as director effective July 6, 2026; no disagreement with the company.
- David Zaccardelli appointed as independent Class II director, term until 2029 annual meeting.
- Zaccardelli is former CEO of Verona Pharma (acquired by Merck 2025), Dova, and Cempra.
- He receives standard non-employee director compensation: $40k annual cash retainer, initial option grant of up to 68k shares or $700k.
- No material transactions or arrangements exist between Zaccardelli and the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312526297454/0001193125-26-297454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312526297454/vor-20260706.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-297454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer